Topoisomerase I poisons and suppressors as anticancer drugs.
about
Inhibition of topoisomerase I cleavage activity by thiol-reactive compounds: importance of vicinal cysteines 504 and 505Structure and mechanism of the rebeccamycin sugar 4'-O-methyltransferase RebMImmunodetection of human topoisomerase I-DNA covalent complexesAnticancer agent shikonin is an incompetent inducer of cancer drug resistanceDissociation of minor groove binders from DNA: insights from metadynamics simulations.Ensemble and single-molecule fluorescence spectroscopic study of the binding modes of the bis-benzimidazole derivative Hoechst 33258 with DNAAcid-base and electronic structure-dependent properties of Hoechst 33342.A phase I study of the safety and pharmacokinetics of edotecarin (J-107088), a novel topoisomerase I inhibitor, in patients with advanced solid tumors.Design, synthesis, and biological evaluation of O-2-modified indenoisoquinolines as dual topoisomerase I-tyrosyl-DNA phosphodiesterase I inhibitors.DNA sequence recognition by the indolocarbazole antitumor antibiotic AT2433-B1 and its diastereoisomer.Mechanism targeted discovery of antitumor marine natural products.Shikonin and its analogs inhibit cancer cell glycolysis by targeting tumor pyruvate kinase-M2.Mechanisms behind the inhibition of lung adenocarcinoma cell by shikoninDNA topoisomerases as targets for anticancer drugs.RebG- and RebM-catalyzed indolocarbazole diversification.Novel treatments and therapies in development for pancreatic cancer.UbcH7 regulates 53BP1 stability and DSB repairCellular pharmacology studies of shikonin derivatives.Topoisomerase I inhibitors, shikonin and topotecan, inhibit growth and induce apoptosis of glioma cells and glioma stem cells.Alcohol-, diol-, and carbohydrate-substituted indenoisoquinolines as topoisomerase I inhibitors: investigating the relationships involving stereochemistry, hydrogen bonding, and biological activity.Selective Inhibition of Bacterial Topoisomerase I by alkynyl-bisbenzimidazolesFlavonoids: A versatile source of anticancer drugs.Selective permeabilization of cervical cancer cells to an ionic DNA-binding cytotoxin by activation of P2Y receptors.Secondary metabolites as DNA topoisomerase inhibitors: A new era towards designing of anticancer drugs.Camptothecins in clinical development.Role of caspases in the regulation of apoptotic pancreatic islet beta-cells death.Tangeretin sensitizes cisplatin-resistant human ovarian cancer cells through downregulation of phosphoinositide 3-kinase/Akt signaling pathway.Role of DNA mismatch repair in apoptotic responses to therapeutic agents.Nec-1 enhances shikonin-induced apoptosis in leukemia cells by inhibition of RIP-1 and ERK1/2Identification, synthesis, and biological evaluation of metabolites of the experimental cancer treatment drugs indotecan (LMP400) and indimitecan (LMP776) and investigation of isomerically hydroxylated indenoisoquinoline analogues as topoisomerase IDesign, synthesis, and biological evaluation of 14-substituted aromathecins as topoisomerase I inhibitorsA "Double-Edged" Scaffold: Antitumor Power within the Antibacterial Quinolone.Tracking the cell cycle origins for escape from topotecan action by breast cancer cells.Physicochemical characterization of 9-aminocamptothecin in aqueous solutions.Pyridoxal 5'-phosphate inactivates DNA topoisomerase IB by modifying the lysine general acid.Polyphenols as key players for the antileukaemic effects of propolis.Active site mutations in DNA topoisomerase I distinguish the cytotoxic activities of camptothecin and the indolocarbazole, rebeccamycin.Directing topoisomerase I mediated DNA cleavage to specific sites by camptothecin tethered to minor- and major-groove ligands.Heat Shock Proteins in Dermatophytes: Current Advances and PerspectivesAntiproliferative activities of Fagara xanthoxyloides and Pseudocedrela kotschyi against prostate cancer cell lines.
P2860
Q24299998-F3046197-6980-4CA3-8910-48FB04EEA5C6Q24646712-BC4D5F35-3614-4FDC-9C66-832538586C2AQ27324108-1D2CE97F-7C80-4282-9BDD-8938FA11DE0BQ28484828-82829400-F71C-4C5A-B9C5-D10F981D16F1Q30484039-52A187F7-DF39-4AA5-AB16-D0347CC48CFCQ33186639-7A6631E6-9135-430E-88A8-3FE822FEBC8AQ33215880-35D9C1BA-3896-4091-A4CB-DB89B0AB9E20Q33371838-479D6553-463A-4F6C-AA01-47BC302272CAQ33662415-D0456ECA-B8EE-4CFB-911C-03367F819904Q33827012-F6D10946-ED16-4612-B2C2-41B48E6D1845Q34012630-89CCEF22-C347-46B1-9484-E390E5756382Q34180241-E6D12CFA-7CBC-4107-82A6-2215D4D6D774Q34277873-89EB9E0E-E3F8-4FBA-B75D-75009B51BB0AQ34448509-4E581FD9-4D70-43BB-B16F-EACBA32845B4Q34507343-2BEAAF28-68B6-420A-9569-C4E46BACAC88Q34660844-706E06A9-2F2E-4A15-A93C-EBF433D7828AQ34709157-4118F0F5-3534-441A-837B-2190E0B8D3CCQ34774883-94FE204E-4785-40FA-AC07-B671FB3479DDQ35058674-B76D2EBD-C6AA-4D9D-ACC1-B4610E73C153Q35152039-810B2E8F-EF52-4997-A8ED-D58E4C90BADEQ35216986-2DE7C166-EF58-430E-8783-B25B695036F2Q35533265-C11626D1-EDE1-4E81-83AB-20E0C66497A4Q35621198-6D8667DF-C7EF-4D2C-91C5-E352B902DA2BQ35646690-6624C9AE-B1A9-4683-A19E-45C1D389EAE7Q35688238-202105FB-53B4-4A6E-B77F-C9350E51BCEDQ35790490-3CEF7B47-5BAA-41E0-9D4E-AF24B21818CFQ35869232-78B27D44-6821-4099-BA0A-A7F5F0CC4EE0Q35910747-E195F548-94C2-43E3-ACC1-92353B8C2C3BQ36096963-9A0B37FE-80C7-4178-A7C6-778A5043EE38Q36525254-AC2FAC15-DB19-44B9-A2F5-E85B21C25D94Q36882373-3A1549E5-06FC-40BF-866A-2FB9B01FA4F4Q37204002-B6732AE1-928A-466C-88DC-26D3C61D9CC2Q37355096-D81AD4DD-FD31-42CB-932A-24216E54987FQ37538913-F2F4FCF5-83C0-4F0E-8D21-8B6730F22E42Q37592359-1F70B397-A33E-4138-A747-71A50DCC731AQ37688081-92C2C342-873E-4B6B-B134-A0281A7A0551Q38293789-39966703-CB0A-4B14-8393-1865192464A0Q38388416-239226D4-3E87-41B4-83A7-0FB4C89F572AQ38844654-4EC0B274-33B4-4228-87AF-65B429D8D1C6Q38902326-567099B4-A897-4D96-A2C5-4F143F396228
P2860
Topoisomerase I poisons and suppressors as anticancer drugs.
description
2000 nî lūn-bûn
@nan
2000 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Topoisomerase I poisons and suppressors as anticancer drugs.
@ast
Topoisomerase I poisons and suppressors as anticancer drugs.
@en
type
label
Topoisomerase I poisons and suppressors as anticancer drugs.
@ast
Topoisomerase I poisons and suppressors as anticancer drugs.
@en
prefLabel
Topoisomerase I poisons and suppressors as anticancer drugs.
@ast
Topoisomerase I poisons and suppressors as anticancer drugs.
@en
P356
P1476
Topoisomerase I poisons and suppressors as anticancer drugs.
@en
P2093
P356
10.2174/0929867003375489
P577
2000-01-01T00:00:00Z